Last $10.95 USD
Change Today -0.33 / -2.93%
Volume 116.0K
STML On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

stemline therapeutics inc (STML) Snapshot

Open
$11.33
Previous Close
$11.28
Day High
$11.33
Day Low
$10.85
52 Week High
10/1/13 - $47.25
52 Week Low
08/21/14 - $10.51
Market Cap
145.2M
Average Volume 10 Days
132.0K
EPS TTM
$-2.22
Shares Outstanding
13.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STEMLINE THERAPEUTICS INC (STML)

Related News

No related news articles were found.

stemline therapeutics inc (STML) Related Businessweek News

No Related Businessweek News Found

stemline therapeutics inc (STML) Details

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary therapeutics for cancer stem cells and bulk tumors in the United States. It develops SL-401, a clinically active targeted therapy directed to the interleukin-3 receptor, which has completed Phase I/II clinical trials for advanced hematologic cancers; and SL-701, a clinically active therapeutic cancer vaccine that has completed two Phase I/II clinical trials. The company was founded in 2003 and is headquartered in New York, New York.

20 Employees
Last Reported Date: 08/14/14
Founded in 2003

stemline therapeutics inc (STML) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $770.9K
Chief Accounting Officer and Vice President o...
Total Annual Compensation: --
Chief Operating Officer and Corporate Secreta...
Total Annual Compensation: $552.1K
Chief Medical Officer, Head of Research & Dev...
Total Annual Compensation: $516.7K
Compensation as of Fiscal Year 2013.

stemline therapeutics inc (STML) Key Developments

Stemline Therapeutics, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Stemline Therapeutics, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported grant revenue of $71,429. Loss from operations was $6,046,026 compared to $5,155,947 a year ago. Net loss attributable to common stockholders was $6,012,698 or $0.47 per basic and diluted share compared to $5,450,638 or $0.55 per basic and diluted share a year ago. For the six months period, the company reported grant revenue of $142,429. Loss from operations was $15,080,242 compared to $10,485,140 a year ago. Net loss attributable to common stockholders was $15,012,625 or $1.16 per basic and diluted share compared to $10,956,284 or $1.37 per basic and diluted share a year ago.

Stemline Therapeutics, Inc. Announces Opening of SL-401 Investigational New Drug and Start of Clinical Trials in BPDCN and AML

Stemline Therapeutics, Inc. announced the opening of its SL-401 Investigational New Drug (IND) and initiation of a broad clinical development program including trials in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML). SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on cancer stem cells (CSCs) and tumor bulk of many hematologic cancers. SL-401 has completed a physician-sponsored Phase 1/2 trial and demonstrated a tolerable safety profile and clinical activity in multiple indications, including durable complete responses (CRs), in BPDCN and relapsed/refractory AML. Seven of nine evaluable BPDCN patients had objective responses, including 5 CRs. The company has now initiated a corporate-sponsored multicenter, open-label trial in patients with BPDCN and relapsed/refractory AML. This study is designed to accrue at least 60 patients, including a brief lead-in that transitions into a larger expansion stage in these indications. Additional trials in other IL-3R expressing malignancies will follow this year and into early next year.

Stemline Therapeutics, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 03:05 PM

Stemline Therapeutics, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 03:05 PM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: Ivan Bergstein, Founder, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STML:US $10.95 USD -0.33

STML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for STML.
View Industry Companies
 

Industry Analysis

STML

Industry Average

Valuation STML Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 682.9x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 596.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMLINE THERAPEUTICS INC, please visit www.stemline.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.